/assets/img/Leone1.png
/assets/img/Leone3.png

/assets/img/cw-stocks-3.png
/assets/img/red-line.jpg
/assets/img/cw-stocks.png
21° Cweather-icon
/assets/img/Leone1.png
/assets/img/Leone3.png

/assets/img/cw-stocks-3.png
/assets/img/red-line.jpg
/assets/img/cw-stocks.png

Axicabtagene Ciloleucel Approaches EU Approval for DLBCL, PMBCL

Pharma & biotech2018-06-29
19 Views

The European Medicines Agency’s CHMP has recommended approval of axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma.

Source: OncLive

Read More..
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.



Sponsored
Also read